Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

NCT05096494 is registered in ClinicalTrials.gov with Scilex Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05096494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05096494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain
Lead sponsor
Scilex Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 29, 2022
Completion date
May 30, 2023
Enrollment
76 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe acute lower back pain